Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features-Reference-Cited by-同舟云学术

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features

Published:2002-09 Issue:3 Volume:60 Page:469-473
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Krumholtz Jason S,Carvalhal Gustavo F,Ramos Christian G,Smith Deborah S,Thorson Phataraporn,Yan Yan,Humphrey Peter A,Roehl Kimberly A,Catalona William J

Publisher

Elsevier BV

Subject

Urology

Reference23 articles.

1. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer;Catalona;N Engl J Med,1991

2. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening;Catalona;JAMA,1993

3. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients;Stamey;J Urol,1989

4. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination;Catalona;JAMA,1997

5. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening;Humphrey;J Urol,1996

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement;Urologic Oncology: Seminars and Original Investigations;2024-07

2. Emerging Microfluidic Devices for Sample Preparation of Undiluted Whole Blood to Enable the Detection of Biomarkers;ACS Sensors;2023-04-03

3. A smart, practical, deep learning-based clinical decision support tool for patients in the prostate-specific antigen gray zone: model development and validation;Journal of the American Medical Informatics Association;2022-08-30

4. A COMPARATIVE STUDY OF THE RELEVANCE OF DRE, TRUS, AND PSA IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH CARCINOMA OF THE PROSTATE.;GLOBAL JOURNAL FOR RESEARCH ANALYSIS;2021-02-15

5. O ‐glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer;The Prostate;2020-12-21